Overexpression of human C-reactive protein exacerbatesleft ventricular remodeling in diabetic cardiomyopathy

Circulation Journal

Volumn 75, Issue 7, 2011, Pages 1717-1727

  Mano, Yoshinori ^a   Anzai, Toshihisa ^a   Kaneko, Hidehiro ^a   Nagatomo, Yuji ^a   Nagai, Toshiyuki ^a   Anzai, Atsushi ^a   Maekawa, Yuichiro ^a   Takahashi, Toshiyuki ^a   Meguro, Tomomi ^a   Yoshikawa, Tsutomu ^a   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C reactive protein; Diabetes mellitus; Heart failure; Inflammation; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; C REACTIVE PROTEIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; DNA NUCLEOTIDYLEXOTRANSFERASE; GLUTATHIONE PEROXIDASE 3; INTERLEUKIN 6; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISEASE EXACERBATION; ECHOCARDIOGRAPHY; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE; HEART MUSCLE FIBROSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; APOPTOSIS; C-REACTIVE PROTEIN; COLLAGEN TYPE I; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIUM; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; STREPTOZOCIN; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 79959709996     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1199     Document Type: Article

References (58)

1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestiveheart failure: The Framingham study. Am J Cardiol 1974; 34:29-34.
2. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation2007; 115: 3213-3223.
3. An D, Rodrigues B. Role of changes in cardiac metabolism indevelopment of diabetic cardiomyopathy. Am J Physiol Heart CircPhysiol 2006; 291: H1489-H1506.
4. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, et al. Recipes for creating animal models of diabetic cardiovasculardisease. Circ Res 2007; 100: 1415-1427.
5. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altmann C, et al. Transgenic activation of the kallikrein-kinin system inhibitsintramyocardial inflammation, endothelial dysfunction and oxidativestress in experimental diabetic cardiomyopathy. FASEB J 2005;19: 2057-2059.
6. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bucker-Gartner C, Sobirey M, et al. Inhibition of p38 mitogen-activatedprotein kinase attenuates left ventricular dysfunction by mediatingpro-inflammatory cardiac cytokine levels in a mouse model of diabetesmellitus. Diabetologia 2006; 49: 2507-2513.
7. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S, etal. Anti-inflammatory effects of atorvastatin improve left ventricularfunction in experimental diabetic cardiomyopathy. Diabetologia2007; 50: 1977-1986.
8. Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, etal. Elevated C-reactive protein levels in the development of type 1diabetes. Diabetes 2004; 53: 2569-2573.
9. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction ofcardiovascular events in the Framingham Offspring Study. Circulation2004; 110: 380-385.
10. Oda E, Kawai R. Tentative cut point of high-sensitivity C-reactiveprotein for a component of metabolic syndrome in Japanese. Circ J2009; 73: 755-759.
11. Goyal BR, Mesariya P, Goyal RK, Mehta AA. Effect of telmisartanon cardiovascular complications associated with streptozotocindiabetic rats. Mol Cell Biochem 2008; 314: 123-131.
12. Shah SJ, Marcus GM, Gerber IL, McKeown BH, Vessey JC, Jordan MV, et al. High-sensitivity C-reactive protein and parameters ofleft ventricular dysfunction. J Card Fail 2006; 12: 61-65.
13. Hirasawa Y, Nakagomi A, Kobayashi Y, Katoh T, Mizuno K. Shorttermamiodarone treatment attenuates the production of monocytecytokines and chemokines by C-reactive protein and improves cardiacfunction in patients with idiopathic dilated cardiomyopathyand ventricular tachycardia. Circ J 2009; 73: 639-646.
14. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: Prognostic value and theeffect of valsartan. Circulation 2005; 112: 1428-1434.
15. Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, et al. C-reactive protein and risk of heart failure: TheRotterdam Study. Am Heart J 2006; 152: 514-520.
16. Araujo JP, Lourenco P, Azevedo A, Frioes F, Rocha-Goncalves F, Ferreira A, et al. Prognostic value of high-sensitivity C-reactiveprotein in heart failure: A systematic review. J Card Fail 2009; 15:256-266.
17. Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG. Relationship of high-sensitivity C-reactive protein to prognosisand other prognostic markers in outpatients with heart failure. AmHeart J 2007; 153: 1048-1055.
18. Nakatani D, Sakata Y, Mizuno H, Shimizu M, Suna S, Usami M, et al. Impact of diabetes mellitus on rehospitalization for heart failureamong survivors of acute myocardial infarction in the percutaneouscoronary intervention era. Circ J 2009; 73: 662-666.
19. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, et al. C-reactive protein upregulates angiotensin type 1 receptors invascular smooth muscle. Circulation 2003; 107: 1783-1790.
20. Zhong Y, Li SH, Liu SM, Szmitko PE, He XQ, Fedak PW, et al. C-Reactive protein upregulates receptor for advanced glycationend products expression in human endothelial cells. Hypertension2006; 48: 504-511.
21. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissueplasminogen activator activity in human aortic endothelial cells:Evidence that C-reactive protein is a procoagulant. ArteriosclerThromb Vasc Biol 2005; 25: 2216-2221.
22. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005; 2: 29-36.
23. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitricoxide production and inhibits angiogenesis. Circulation 2002; 106:913-919.
24. Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE, et al. Impaired endothelial function in C-reactive protein overexpressingmice. Atherosclerosis 2008; 201: 318-325.
25. Zimmermann O, Bienek-Ziolkowski M, Wolf B, Vetter M, Baur R, Mailander V, et al. Myocardial inflammation and non-ischaemicheart failure: Is there a role for C-reactive protein? Basic Res Cardiol2009; 104: 591-599.
26. Takahashi T, Anzai T, Kaneko H, Mano Y, Anzai A, Nagai T, et al. Increased C-reactive protein expression exacerbates left ventriculardysfunction and remodeling after myocardial infarction. Am JPhysiol Heart Circ Physiol 2010; 299: H1795-H1804.
27. Matsushima S, Kinugawa S, Ide T, Matsusaka H, Inoue N, Ohta Y, et al. Overexpression of glutathione peroxidase attenuates myocardialremodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 2006; 291: H2237-H2245.
28. Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, Ohta Y, etal. Angiotensin II type 1 receptor blocker attenuates myocardial remodelingand preserves diastolic function in diabetic heart. HypertensRes 2007; 30: 439-449.
29. Kohno T, Anzai T, Naito K, Miyasho T, Okamoto M, Yokota H, etal. Role of high-mobility group box 1 protein in post-infarction healingprocess and left ventricular remodelling. Cardiovasc Res 2009;81: 565-573.
30. Maekawa Y, Anzai T, Yoshikawa T, Sugano Y, Mahara K, Kohno T, et al. Effect of granulocyte-macrophage colony-stimulating factorinducer on left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2004; 44: 1510-1520.
31. Sugano Y, Anzai T, Yoshikawa T, Maekawa Y, Kohno T, Mahara K, et al. Granulocyte colony-stimulating factor attenuates early ventricularexpansion after experimental myocardial infarction. CardiovascRes 2005; 65: 446-456.
32. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Escher F, Bucker-Gartner C, et al. Cardioprotective and anti-inflammatoryeffects of interleukin converting enzyme inhibition in experimentaldiabetic cardiomyopathy. Diabetes 2007; 56: 1834-1841.
33. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, et al. Tumor necrosis factor-alpha antagonism protectsfrom myocardial inflammation and fibrosis in experimental diabeticcardiomyopathy. Basic Res Cardiol 2007; 102: 500-507.
34. Westermann D, Walther T, Savvatis K, Escher F, Sobirey M, Riad A, et al. Gene deletion of the kinin receptor B1 attenuates cardiacinflammation and fibrosis during the development of experimentaldiabetic cardiomyopathy. Diabetes 2009; 58: 1373-1381.
35. Zhou G, Li X, Hein DW, Xiang X, Marshall JP, Prabhu SD, etal. Metallothionein suppresses angiotensin II-induced nicotinamideadenine dinucleotide phosphate oxidase activation, nitrosative stress,apoptosis, and pathological remodeling in the diabetic heart. J AmColl Cardiol 2008; 52: 655-666.
36. Iwata K, Nishinaka T, Matsuno K, Yabe-Nishimura C. Increasedgene expression of glutathione peroxidase-3 in diabetic mouse heart. Biol Pharm Bull 2006; 29: 1042-1045.
37. Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, et al. Lack of the antioxidant enzyme glutathione peroxidase-1accelerates atherosclerosis in diabetic apolipoprotein E-deficientmice. Circulation 2007; 115: 2178-2187.
38. Chiu J, Farhangkhoee H, Xu BY, Chen S, George B, ChakrabartiS. PARP mediates structural alterations in diabetic cardiomyopathy. J Mol Cell Cardiol 2008; 45: 385-393.
39. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, et al. C-reactive protein accelerates the progression of atherosclerosis inapolipoprotein E-deficient mice. Circulation 2004; 109: 647-655.
40. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, et al. Increased thrombosis after arterial injury in humanC-reactive protein-transgenic mice. Circulation 2003; 108: 512-515.
41. Wang D, Oparil S, Chen YF, McCrory MA, Skibinski GA, Feng W, et al. Estrogen treatment abrogates neointima formation in humanC-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol2005; 25: 2094-2099.
42. Xing D, Hage FG, Chen YF, McCrory MA, Feng W, Skibinski GA, et al. Exaggerated neointima formation in human C-reactive proteintransgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol 2008; 172: 22-30.
43. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice withcardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-635.
44. Chen D, Assad-Kottner C, Orrego C, Torre-Amione G. Cytokinesand acute heart failure. Crit Care Med 2008; 36: S9-S16.
45. Connelly KA, Boyle AJ, Kelly DJ. Angiotensin II and the cardiaccomplications of diabetes mellitus. Curr Pharm Des 2007; 13:2721-2729.
46. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87:1123-1132.
47. Symeonides P, Koulouris S, Vratsista E, Triantafyllou K, Ioannidis G, Thalassinos N, et al. Both ramipril and telmisartan reverse indicesof early diabetic cardiomyopathy: A comparative study. EurJ Echocardiogr 2007; 8: 480-486.
48. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystanderor proatherogenic culprit? The verdict is still out. Circulation 2006;113: 2128-2134.
49. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidasesas therapeutic targets in cardiovascular diseases. Trends PharmacolSci 2003; 24: 471-478.
50. Qin F, Simeone M, Patel R. Inhibition of NADPH oxidase reducesmyocardial oxidative stress and apoptosis and improves cardiacfunction in heart failure after myocardial infarction. Free Radic BiolMed 2007; 43: 271-281.
51. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemiainducedapoptosis in mouse myocardium: Mitochondrial cytochromeC-mediated caspase-3 activation pathway. Diabetes 2002; 51: 1938 -1948.
52. Fujii H, Li SH, Szmitko PE, Fedak PW, Verma S. C-reactive proteinalters antioxidant defenses and promotes apoptosis in endothelialprogenitor cells. Arterioscler Thromb Vasc Biol 2006; 26:2476-2482.
53. Yang J, Wang J, Zhu S, Chen X, Wu H, Yang D, et al. C-reactiveprotein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes. Mol Cell Biochem2008; 310: 215-226.
54. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, Sgaramella G, et al. Increased cardiomyocyte apoptosis and changes in proapoptoticand antiapoptotic genes bax and bcl-2 during left ventricularadaptations to chronic pressure overload in the rat. Circulation1999; 99: 3071-3078.
55. Tron K, Manolov DE, Rocker C, Kachele M, Torzewski J, Nienhaus GU. C-reactive protein specifically binds to Fcgamma receptortype I on a macrophage-like cell line. Eur J Immunol 2008; 38:1414-1422.
56. Stein MP, Mold C, Du Clos TW. C-reactive protein binding tomurine leukocytes requires Fc gamma receptors. J Immunol 2000;164: 1514-1520.
57. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. Themajor receptor for C-reactive protein on leukocytes is fcgammareceptor II. J Exp Med 1999; 190: 585-590.
58. Szalai AJ, McCrory MA. Varied biologic functions of C-reactiveprotein: Lessons learned from transgenic mice. Immunol Res 2002;26: 279-287.